Vaderis Therapeutics Announces $152.5 Million Series B Financing and Initiation of the Global Phase 3 HEROIC Study of Engasertib for Hereditary Hemorrhagic Telangiectasia

• $152.5 million Series B financing co-led by Life Sciences at Goldman Sachs Alternatives and TCGX, with participation from Omega Funds, EQT Life Sciences, Perceptive Life Sciences, Medicxi (CalPERS), Kalehua Capital Partners, and existing investors Medicxi and Droia
• Provides the company with capital needs through potential U.S. regulatory approval of engasertib
• Marks the company's transition into pivotal-stage development with initiation of the global Phase 3 HEROIC study evaluating engasertib in patients with moderate-to-severe hereditary hemorrhagic telangiectasia (HHT).

Basel, Switzerland and Lincolnshire, Il. - August 11, 2026 - Vaderis Therapeutics, a clinical-stage biopharmaceutical company focused on developing targeted therapies for rare vascular diseases, today announced the closing of a private $152.5 million Series B financing and initiation of HEROIC, the company's global Phase 3 clinical study evaluating engasertib (VAD044) in patients with hereditary hemorrhagic telangiectasia (HHT).

Together, these milestones mark a significant step forward in the development of engasertib, an investigational oral allosteric AKT inhibitor. Engasertib is positioned to become the first approved therapy specifically developed for people living with HHT, a rare genetic vascular disorder that currently has no approved treatment options worldwide.

The Series B financing, supported by both new and existing investors, reflects strong confidence in the potential of engasertib to address significant unmet needs in HHT. The proceeds from the financing are expected to fund the company's planned operations through regulatory submissions and potential U.S. regulatory approval.

The financing and initiation of HEROIC follows publication of positive proof-of-concept and long-term extension data for engasertib in The New England Journal of Medicine, which demonstrated clinically meaningful and sustained improvements across multiple measures of disease in patients with HHT. These data established the scientific foundation for advancing engasertib into pivotal development and its potential to address the significant unmet needs of patients living with HHT.

"Today represents a defining moment for HHT patients ," said Azmi Nabulsi, MD, MPH, President and Chief Executive Officer of Vaderis Therapeutics. "Closing this financing and initiating HEROIC as the first Phase 3 study utilizing a molecule specifically developed for HHT marks an exciting new chapter. This milestone reflects the dedication of our patients, investigators, study teams, and advocacy organizations, to whom we extend our deepest gratitude. We are also thankful to our investors for their confidence and support, which have been essential in bringing us to this point."

"Since partnering with Vaderis at its founding, Medicxi has seen the company consistently translate strong science into meaningful clinical progress," said Giovanni Mariggi, co-founder and Partner, Medicxi. "The advancement of engasertib into Phase 3 represents the culmination of years of disciplined execution, scientific innovation and close collaboration with the HHT community. Building on the important contributions of clinicians, researchers and companies that have advanced the field, we are proud to continue supporting Vaderis as it pioneers a regulatory pathway for therapies specifically developed for HHT, while working to bring the first such treatment to patients.

"Vaderis has generated compelling clinical evidence supporting targeted AKT inhibition as a novel treatment approach for HHT," said Colin Walsh, PhD, Managing Director, Life Sciences at Goldman Sachs Alternatives. "The company's strong scientific foundation, disciplined execution and clear focus on addressing a significant unmet medical need gave us conviction in both the financing and the Phase 3 program. We are pleased to partner with Vaderis and a high quality investor syndicate to advance engasertib through this important stage of development."

Phase 3 HEROIC Study Now Underway

HEROIC is a global, randomized, double-blind, placebo-controlled Phase 3 clinical study designed to evaluate the efficacy and safety of once-daily oral engasertib in patients with moderate-to-severe HHT. The study is expected to enroll patients across sites in North America, South America and Europe.

"HHT remains a serious, lifelong disease that places a substantial burden on patients, yet there are still no approved therapies," said Hanny Al-Samkari, MD, Associate Professor of Medicine at Harvard Medical School, The Peggy S. Blitz Endowed Chair in Hematology/Oncology at Mass General Brigham Cancer Institute, and Principal Investigator of the HEROIC study. "As the Principal Investigator of HEROIC, I believe this study has been thoughtfully designed to rigorously evaluate engasertib in a larger patient population and confirm the encouraging findings from the earlier proof-of-concept study."

About Engasertib (VAD044)

Engasertib is an investigational oral selective allosteric inhibitor of AKT1/2 being developed for the treatment of hereditary hemorrhagic telangiectasia (HHT), a rare genetic vascular disorder characterized by recurrent bleeding and arteriovenous malformations. By targeting dysregulated signaling pathways implicated in vascular malformations, engasertib is designed to address the underlying pathophysiology of disease.

Engasertib has not been approved for use in any country for any indication.

About HHT

Hereditary hemorrhagic telangiectasia (HHT) is a rare genetic vascular disorder (prevalence ~1 in 3,800) characterized by recurrent severe epistaxis, anemia, and visceral arteriovenous malformations (AVMs). Despite the significant disease burden, there are currently no approved therapies for HHT globally.

About Vaderis Therapeutics

Vaderis Therapeutics is a science-driven biopharmaceutical company focused on discovering and advancing transformative treatments for rare vascular diseases. By targeting the underlying pathophysiology, the company aims to bring first-in-class targeted therapies to patients in need. Vaderis is headquartered in Basel, Switzerland with a U.S. subsidiary in Lincolnshire, Illinois. For more information, visit www.vaderis.com

About Life Sciences at Goldman Sachs Alternatives

Goldman Sachs (NYSE: GS) is one of the leading investors in alternatives globally, with over $706 billion in assets and more than 30 years of experience. The business invests in the full spectrum of alternatives including private equity, growth equity, venture capital, private credit, real estate, infrastructure, sustainability, and hedge funds. Clients access these solutions through direct strategies, customized partnerships, and open-architecture programs.

The business is driven by a focus on partnership and shared success with its clients, seeking to deliver long-term investment performance drawing on its global network and deep expertise across industries and markets.

Life Sciences at Goldman Sachs Alternatives was established in 2021 and focuses on later-stage venture investments, targeting therapeutic companies in early clinical development with multi-asset portfolios. The Life Sciences team brings decades of experience investing in the sector and leverages the expansive resources of the Goldman Sachs platform to source differentiated investments and partner with companies to enhance value creation.

The alternative investments platform is part of Goldman Sachs Asset Management, which delivers investment and advisory services across public and private markets for the world's leading institutions, financial advisors and individuals. Goldman Sachs has approximately $4.0 trillion in assets under supervision globally as of June 30, 2026.

Media Contact

For Goldman Sachs:
Victoria Zarella
[email protected]

Forward-Looking Statement

This press release contains forward-looking statements regarding the development, regulatory review, and potential approval of engasertib and related programs, the anticipated initiation, timing, and execution of clinical trials, the expected use of proceeds from the financing, and the company's anticipated operational runway. Actual results may differ materially from those described due to risks, uncertainties, and the inherent complexities of clinical development, regulatory review, financing activities, manufacturing, and other factors.

This press release does not constitute an offer to sell or the solicitation of an offer to purchase any securities.

Medical Information

Engasertib has not been approved for use in any country for any indication. Information in this press release is for medical and scientific reference only and is not intended to promote, recommend, or suggest use of this product. The safety and efficacy of engasertib have not been established by any regulatory authority.